Atea Pharmaceuticals, Inc. · NASDAQ:AVIR
Atea Pharmaceuticals — Q2 2025 Earnings Presentation
26 slides from Atea Pharmaceuticals's earnings presentation, Aug 7, 2025
Slide 1: Second Quarter Financial and Business Update
Second Quarter Financial and Business Update August 7, 2025
Slide 2: Disclaimers
DISCLAIMERS Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our curr
Slide 3: Q2 2025 HCV Program and Business Highlights
Q2 2025 HCV Program and Business Highlights HCV Program Update First patient dosed in Phase 3 trial C-BEYOND in US and Canada (April) Four scientific posters presented at EASL 2025 Congress, including final results from global Phase 2 study (May) Hosted KOL event with panel of six HCV experts and pr
Slide 4: Broad Antiviral Pipeline with De-risked Phase 3 Program
Broad Antiviral Pipeline with De-risked Phase 3 Program Therapeutic/ Program Preclinical Phase 1 Phase 2 Phase 3 Milestone Indication Ph 3 C-BEYOND trial (US / Flaviviridae Hepatitis C Canada) first patient dosed Fixed Dose Combination: April 2025 Bemnifosbuvir (BEM) Nucleotide Ph 3 C-FORWARD (outsi
Slide 5: Global HCV: Large Market with Undertreatment of Infections
Global HCV: Large Market with Undertreatment of Infections WHO Worldwide Numbers Chronic HCV is Leading 50 Million 1 Million Cause of Liver Cancer 242,000 in North America, Europe & People Infected1 New Infections Annually 1 Annual Deaths1 Japan2 CDC US: 2.4 – 4 Million Untreated 3, >170K Newly Repo
Slide 6: US HCV: Major Commercial Opportunity Poised for Growth
US HCV: Major Commercial Opportunity Poised for Growth Attractive Near-Term Opportunity Poised for Growth >$20B+ Primarily 2 product No Potential US Market competitors in Opportunity2 market clinical development ~$3B ~$1.5B Potential US government global net sales US net sales initiatives to in 2024
Slide 7: BEM/RZR Second Quarter Highlights
BEM/RZR Second Quarter Highlights Multiple Presentations at EASL 2025 7
Slide 8: Q2 Highlights: Multiple Presentations at EASL Congress May 7-10, 2025
Q2 Highlights: Multiple Presentations at EASL Congress May 7-10, 2025 Four Poster Presentations at the European Association for the Study of the Liver (EASL) Efficacy and Safety of Bemnifosbuvir and Ruzasvir after 8 Weeks of Treatment in Patients with Chronic Hepatitis C Virus (HCV) Infection (TOP-2
Slide 9: Efficacy Primary Endpoint: Robust SVR12 Rates with 98% SVR12
Efficacy Primary Endpoint: Robust SVR12 Rates with 98% SVR12 95% SVR12 Regardless of Adherence 100% 98% 95% 80% Robust 60% potency SVR12 (%) with drug forgiveness 40% 20% 210/215 245/259 0% Overall Treatment adherent Patients regardless of patients: 98% SVR12 treatment adherence: (primary endpoint a
Slide 10: Phase 2 Results: 99% SVR12 in Non-Cirrhotic Treatment Adherent Patients Across Genotypes
Phase 2 Results: 99% SVR12 in Non-Cirrhotic Treatment Adherent Patients Across Genotypes 97% SVR12 Regardless of Adherence Robust SVR12 cure rates in non-cirrhotic Robust potency and drug patients across genotypes forgiveness 100% 100% 99% 99% 100% 100% 100% Overall: 97% 98% 99% SVR12 97% SVR12 80%
Slide 11: BEM/RZR Potential Best-in-Class Pan-Genotypic Regimen
BEM/RZR Potential Best-in-Class Pan-Genotypic Regimen Global Phase 3 Program Update 11
Slide 12: Global HCV Phase 3 Program C-BEYOND in US / Canada & C-FORWARD Outside North America
Global HCV Phase 3 Program C-BEYOND in US / Canada & C-FORWARD Outside North America Open-label: BEM/RZR Regimen vs Active Comparator in Chronic HCV Patients Randomized (1:1) Non-Cirrhotic 8 weeks BEM/RZR FDC Chronic HCV, patients stratified by cirrhosis US / Canada Trial ~N=~748 1:1 12 weeks SOF/VE
Slide 13: Global HCV Phase 3 Program
Global HCV Phase 3 Program C-BEYOND C-FORWARD • Targeting ~120 sites in US and • Targeting ~120 sites in 16 countries Canada outside of North America 13
Slide 14: Potential Best-in-Class Pan-Genotypic Regimen
Potential Best-in-Class Pan-Genotypic Regimen HCV KOL Panel Event Target Best-in-Class Profile 14
Slide 15: Q2 Highlights: HCV KOL Panel Event Held on May 14, 2025
Q2 Highlights: HCV KOL Panel Event Held on May 14, 2025 Leaders in Hepatology, Gastroenterology, Infectious Diseases and HCV Research Eric Lawitz, MD Texas Liver Institute, University of Texas Health San Antonio, US Anthony Martinez, MD University of Buffalo, Erie County Medical Center, US David Wyl
Slide 16: Q2 Highlights: HCV KOL Panel Event Held on May 14, 2025
Q2 Highlights: HCV KOL Panel Event Held on May 14, 2025 • HCV prevalence has not slowed despite existing available DAA treatments. In 2015, there was ~2.5 million people infected in the US, now ≥4 million. • HCV patients have evolved to a younger and more complicated population, and more treatments
Slide 17: BEM/RZR: Target Best-in-Class Profile for HCV
BEM/RZR: Target Best-in-Class Profile for HCV BEM/RZR: Next generation, pan-genotypic, fixed dose regimen • BEM: most potent HCV nucleotide has been shown to be approximately 10-fold more active than sofosbuvir in in vitro studies; ~2,000 individuals exposed to date • RZR: highly potent HCV NS5A inh
Slide 18: Drug-Drug Interaction Profile of BEM/RZR Regimen is a Key Differentiator
Drug-Drug Interaction Profile of BEM/RZR Regimen is a Key Differentiator -- ~80% of HCV Patients Take Concomitant Medications1 Healthcare Providers Prefer Therapies Convenient to Prescribe Drug BEM/RZR MAVYRET® EPCLUSA® Oral Contraceptives2 Protease Inhibitor-Containing HIV Drugs Statins Immunosuppr
Slide 19: BEM/RZR Second Quarter Highlights: New Quantitative Market Research
BEM/RZR Second Quarter Highlights New Quantitative Market Research 19
Slide 20: Recent US Quantitative Market Research
Recent US Quantitative Market Research DAA Prescribers Reveal High Preference for BEM/RZR % OF PATIENTS LIKELY TO BE PRESCRIBED BEM/RZR IQVIA independent quantitative market research, with 153 top US DAA prescribers (86 GI/Hepatologists, 34 IDs and 33 IMs). 48% 76% Non-Cirrhotic Patients The prescri
Slide 21: Strong Preference for BEM/RZR Consistent Across Studies
Strong Preference for BEM/RZR Consistent Across Studies US Prescriber Market Research Studies Over Time Consistently Predict Significant BEM/RZR Product Market Share December 2023 November 2024 June 2025 N = 157 N = 77 N = 153 Despite high satisfaction with current therapies, Predicted multiple inde
Slide 22: Financial and Business Update
Financial and Business Update 2nd Quarter 2025 Results 22
Slide 23: Financial Update
Financial Update Condensed Consolidated Statement of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses Research and development $ 32,275 $ 34,696 $ 61,859 $ 92,
Slide 24: Financial Update
Financial Update 24 Selected Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) June 30, 2025 December 31, 2024 Cash, cash equivalents and marketable securities $ Working capital” Total assets Total liabilities Total stockholder's equity 379,713 $ 365,485 391,605 27,189 364,416 454
Slide 25: Business Update Q2 2025
Business Update Q2 2025 Financial Repurchase of up to $25 million of the Company’s common stock was authorized and initiated in April 2025. Initiative reflects Company’s commitment to return capital to shareholders, while maintaining capacity to complete global Phase 3 HCV program. As of June 30, 20
Slide 26: 225 Franklin Street Suite 2100 Boston MA USA 02110
225 Franklin Street Suite 2100 Boston MA USA 02110 www.ateapharma.com 26